Around 4,000 people are set to benefit from a step-change in treatment for early breast cancer following today’s (17 June 2022) provisional approval by NICE of abemaciclib in combination with hormone therapy as an option after surgery.
Taken as a twice-daily pill, abemaciclib works by targeting and inhibiting proteins in cancer cells which allow the cancer to divide and grow.
Read more – NICE (17/6/22)